🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Gujarat Themis Biosyn Limited GUJTHEM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.gtbl.in
Company Profile ↓
₹350.95
-1.61% 1Y
Mkt Cap₹4,567.67 Cr
P/E78.51
P/B13.76
Div. Yield0.18%
52W High₹469.14
52W Low₹226.53
Book Value₹26.41
EPS (TTM)₹4.47

Company Overview

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.3%.

Healthy Margins

Maintains a net profit margin of 28.0%.

Recent Developments

  • Mar 2026 Revenue of ₹165.82 Cr (+10.0% YoY); net profit ₹46.69 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.1%, earnings +22.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.8%, profit CAGR -7.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.83%
1 Year:22.10%

Compounded Profit Growth

5 Years:-6.96%
1 Year:22.90%

Stock Price Performance

1 Year:-1.61%
6 Months:-1.94%
3 Months:-1.34%
1 Month:-15.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 51% of range
₹226.53 ₹469.14
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.55 · Neutral
Price Performance
1M-15.03%
3M-1.34%
6M-1.94%
1Y-1.61%
Valuation vs Sector

P/E of 78.51 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 28.0%.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 78.5.
  • Earnings shrank at -7.0% CAGR over 5 years.
  • Trading 25.2% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
78.51
Industry PE
36.43
Forward P/E est.
63.88
PEG Ratio
-
Book Value
₹26.41
Price to Book
13.76
P/S
27.23
EV/EBITDA
50.39
Dividend Yield
0.18%

Growth (CAGR)

Revenue 5Y
3.83%
Profit 5Y
-6.96%
Revenue (YoY)
22.10%
Earnings (YoY)
22.90%

Profitability & Returns

ROCE
15.33%
ROE
16.22%
ROA
9.27%
Profit Margin
28.02%
Op Margin
38.41%
Gross Margin
66.94%
EPS (Latest Qtr)
₹1.00
EPS (TTM)
₹4.47

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
0.93
Current Ratio
1.12
Debt
₹161.81 Cr
Total Assets
₹503.43 Cr
Current Assets
₹88.78 Cr
Working Capital
₹9.64 Cr

Ownership

Promoter Holding
60.27%
Chg in Prom Hold
-11.72%
FII / Inst Holding
3.17%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹4,567.67 Cr
Total Revenue (TTM)
₹173.74 Cr
EBITDA
₹82.66 Cr
Free Cash Flow
₹-123.76 Cr
Operating Cash Flow
₹48.78 Cr
Shares Outstanding
₹13.02 Cr
Gross Margin
66.94%
Payout Ratio
14.99%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GUJTHEM Gujarat Themis Biosyn Limited NSEPHARMA 350.95 78.51 ₹4,567.67 Cr 0.18% 15.33% 16.22% 3.83% -6.96%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --37.74 Cr35.87 Cr42.35 Cr43.37 Cr44.23 Cr
Cost of Revenue --8.35 Cr8.00 Cr7.44 Cr7.25 Cr4.90 Cr
Gross Profit --29.39 Cr27.88 Cr34.91 Cr36.12 Cr39.33 Cr
Operating Expenses --14.58 Cr15.99 Cr16.93 Cr18.70 Cr24.01 Cr
Operating Income --14.81 Cr11.89 Cr17.98 Cr17.42 Cr15.32 Cr
EBITDA --17.39 Cr14.20 Cr21.76 Cr21.72 Cr20.28 Cr
Interest Expense --7.14 L4.21 L4.04 L96.04 L1.91 Cr
Pretax Income --16.09 Cr12.12 Cr18.76 Cr16.87 Cr14.34 Cr
Tax Provision --4.09 Cr3.06 Cr4.50 Cr4.41 Cr3.45 Cr
Net Income --12.00 Cr9.06 Cr14.26 Cr12.46 Cr10.89 Cr
Diluted EPS --1.100.831.311.141.00

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -148.13 Cr169.82 Cr150.80 Cr165.82 Cr
Cost of Revenue -30.78 Cr41.61 Cr31.88 Cr27.58 Cr
Gross Profit -117.35 Cr128.21 Cr118.92 Cr138.24 Cr
Operating Expenses -44.84 Cr52.65 Cr55.45 Cr75.63 Cr
Operating Income -72.51 Cr75.55 Cr63.47 Cr62.61 Cr
EBITDA -80.14 Cr83.54 Cr71.55 Cr77.96 Cr
Interest Expense -9.48 L14.25 L36.40 L2.95 Cr
Pretax Income -77.46 Cr79.33 Cr65.54 Cr62.09 Cr
Tax Provision -19.50 Cr20.17 Cr16.77 Cr15.41 Cr
Net Income -57.97 Cr59.16 Cr48.77 Cr46.69 Cr
Diluted EPS 4.005.325.434.48-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -166.33 Cr221.11 Cr301.31 Cr503.43 Cr
Current Assets -61.73 Cr47.56 Cr51.97 Cr88.78 Cr
Cash & Equivalents -6.05 Cr6.47 Cr11.69 Cr3.12 Cr
Inventory -14.62 Cr3.33 Cr5.05 Cr15.42 Cr
Receivables -17.91 Cr27.03 Cr31.24 Cr60.92 Cr
Total Liabilities -17.18 Cr19.74 Cr52.93 Cr215.66 Cr
Current Liabilities -15.28 Cr16.16 Cr20.56 Cr79.15 Cr
Long Term Debt -0029.64 Cr128.06 Cr
Total Debt -41.91 L2.77 Cr30.47 Cr161.81 Cr
Total Equity -149.15 Cr201.38 Cr248.38 Cr287.77 Cr
Shares Outstanding -10.90 Cr10.90 Cr10.90 Cr10.90 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -39.48 Cr64.21 Cr91.06 Cr48.78 Cr
Investing Cash Flow --20.41 Cr-55.21 Cr-111.82 Cr-172.28 Cr
Financing Cash Flow --13.27 Cr-8.59 Cr26.01 Cr114.93 Cr
Capital Expenditure --23.70 Cr-74.64 Cr-116.15 Cr-172.53 Cr
Free Cash Flow -15.77 Cr-10.43 Cr-25.09 Cr-123.76 Cr
Net Change in Cash -5.79 Cr41.43 L5.26 Cr-8.57 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -79.2%75.5%78.9%83.4%
Operating Margin % -49.0%44.5%42.1%37.8%
Net Margin % -39.1%34.8%32.3%28.2%
ROE % -38.9%29.4%19.6%16.2%
ROCE % -48.0%36.9%22.6%14.8%

Shareholding Pattern

Insiders
60.27%
Institutions
3.17%
Public Float
7.99%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GUJTHEM

Google News Sat, 19 Sep 2026

Gujarat Themis Biosyn Limited (GUJTHEM.NS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE9tZ1EwVHZ0bnZIMmEzbmlYVDVfMUdYOTZJX3FLZHpCWU5ISHV4UmlQTlhKY3gtUjdyRFE1R3JpQUU2TjBhbzBCV25kUkM3MkFkY3M0Y2hwb2FLajRibFBzUkZoUEtlSzN6R3BTS0hvQXE?oc=5" target="_blank">Gujarat Themis B…

Google News ue, 25 Aug 2026

News by CNBC TV18 on TradingView, 2026-08-26 — cnbctv:40ab3aab0094b:0 - TradingView

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5iR2hIazBxbXdHdWQ0bFI4aHlTT2VuTmZLZ0NsTDdWRGpYQ2xhQ3hfWTR5Q1cwSm1iNWdMWXFjYU81Rm4xXzNadXdiNTZTQ0l6c1B3X05zdXRpcEtNQlZab2ZKQWNkMWM?oc=5" target="_blank">News by CNBC TV18 on Trading…

Google News Wed, 30 Sep 2026

Gujarat Themis Biosyn Limited Approves Dividend for the Financial Year Ended 31 March, 2026 - www.marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPRFdFR2JhTmRxdTJzUno1clB0M0k4amlUZ3VLa0ZfNGhhc1VJMDB2OFBFRnY4RHMxaS03NmRlUWJuXzVfNHFqR2liMnhXR0UxcjN6QlRpa3Fka3VBR1FTc1U3NkZ1czBsQjQ5WXNYZzBvMm80aHk5Z181UlZDMmEtYVI2OHdwaGVyeDVybm…

Google News Mon, 01 Jun 2026

Gujarat Themis Biosyn's (NSE:GUJTHEM) Anemic Earnings Might Be Worse Than You Think - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPbmlCdlkwTkItaFJ3RHhCOXlQZ1ZoTC1xYkVRTXdKaUk5OHZwbFNSdXh0ZkpuM05NLVZLM0FxVG9acm1JblFNX2gxRk1NcjBDZlItUVBNZGI5SjM5OGZPTDlEYUpfcWVoSFVNYm1wVElpSXhVbUhFRXdnc09BOFhMVG03UzlTcEkzMzFsWD…

Google News ue, 16 Jun 2026

Gujarat Themis Biosyn Share Price Target 2026: Rs 460 Analyst Forecast - Univest

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9TNEUwM1Utb1VsYTdtUkV1Q2V0MHlBTkx1WERCdkFSNkpvR0ZXQWpJN2gzdG5xbEVOc0gwaTFpZU5DaF9OaXIwSlRhM1QwM2ttajFSejV3em1BR0t1Uzl6V2JNWFRLc0NYY2ZnQjNET0JOdVE5dGFpM3ln?oc=5" target="_blank">Guj…

Google News ue, 13 Oct 2026

GUJTHEM Q2 2026 Earnings: Revenue Climbs ~10% YoY, Shares Slip 1.82% - EBITDA Analysis - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxORjVWS3poZ3hxcUxvMENOamlldTRMZGNoR2NpTnBocm5feHdnQmNyTHk1YWNILTI2V2h4T1VQX3gwQ0JGR3VtTnVjQkw2NlVYbGNhSWwtNzBfaUVpeGN4YmxSaDZZUWxWV3d4Q1UyNkhkcjZxR2tNaFJIaGlmRnM1d1dqY21TWjU3OXVHbk…

GUJTHEM — Frequently Asked Questions

What is the current share price of Gujarat Themis Biosyn Limited (GUJTHEM)?

As of 2026-10-23 04:58 IST, Gujarat Themis Biosyn Limited (GUJTHEM) trades at ₹350.95 on NSE. Its 52-week range is ₹226.53 to ₹469.14.

What is the market capitalisation of GUJTHEM?

Gujarat Themis Biosyn Limited (GUJTHEM) has a market capitalisation of ₹4,567.67 Cr on NSE.

What is the P/E ratio of GUJTHEM?

GUJTHEM trades at a trailing price-to-earnings (P/E) ratio of 78.51. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 13.76.

Does GUJTHEM pay a dividend?

Gujarat Themis Biosyn Limited (GUJTHEM) currently offers a dividend yield of 0.18%.

What is the return on equity (ROE) of GUJTHEM?

GUJTHEM has a return on equity (ROE) of 16.22%. Its return on capital employed (ROCE) is 15.33%.

Is GUJTHEM a good stock to buy?

This page provides a data-driven analysis of Gujarat Themis Biosyn Limited (GUJTHEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space